TICKERNERD
Menu
ABOSABOSHealthcare · Biotechnology

ABOS Stock Forecast: Acumen Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$2.29
−3.78% on the day

The 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +249.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 29 Oct 2026 — in the upper half.

Market cap
$163.4M
Ticker Nerd rank
62/ 100
Median analyst target
$8.00
Analysts covering
6
Revenue$0.0
Operating income−$32.6M
Net income−$32.7M
Free cash flow−$18.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.2%
1M
+2.0%
YTD
+8.5%
1Y
+1.3%
From 52W high
−32.0%
From 52W low
+47.7%
$1.55
$3.37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Acumen Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
62/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Growth
82
Momentum
76
Size
69
Issuance
68
Revisions
39
Volatility
37
Value
34
Quality
19

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ABOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26ABOSHigh $10.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $5.00Median $8.00High $10.00

The green dot is the last close — the median target sits +249.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Sept 2026BTIGReiteratesBuy$8.00
15 Sept 2026CitigroupMaintainsBuy$4.00 → $5.00
26 Mar 2026BTIGReiteratesBuy$8.00
26 Mar 2026BTIGReiteratesBuy—
16 Mar 2026BTIGMaintainsBuy—
27 Jan 2026BTIGMaintainsBuy—
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
17 June 2025CitigroupInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025UBSMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024UBSMaintainsBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
25 July 2024CitigroupInitiatesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
31 Mar 2024UBSMaintainsBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—
12 Dec 2023Deutsche BankInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ABOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ABOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Acumen Pharmaceuticals, Inc. returned +1.3% against +13.1% for the S&P 500, dividends included.

ABOS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26ABOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Acumen Pharmaceuticals, Inc. (ABOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
3.0×

Cheaper than 31% of US stocks

EV / EBITDA
−1.1×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−162.7%

Higher than 9% of US stocks

Return on assets
−57.5%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Acumen Pharmaceuticals, Inc. (ABOS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acumen Pharmaceuticals, Inc. has a market value of $163.4M and an enterprise value of $111.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$91.8M.

  • Acumen Pharmaceuticals, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.3M.

  • Trailing P/E: −1.2×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Acumen Pharmaceuticals, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ABOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABOSAcumen Pharmaceuticals, Inc.$163.4M62
PEPGPepGen Inc.$166.9M39
VRXAVERAXA Biotech AG$166.9M23
PDSBPDS Biotechnology Corp.$162.8M81
ANTXAN2 Therapeutics, Inc.$168.6M71
ALXOALX Oncology Holdings, Inc.$168.7M53
TRDAEntrada Therapeutics, Inc.$170.8M50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Acumen Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABOS news & analysis

Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout

Seeking Alpha · 28 Oct 2026positive

Seeking Alpha rates Acumen Pharmaceuticals a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. The article estimates fair value at $2.57 per share and says the thesis depends on efficacy and manageable ARIA risk.

Why it matters — The upcoming trial readout and its potential efficacy and safety findings are central to the article's assessment of ABOS.

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Seeking Alpha · 26 Oct 2026neutral

The provided excerpt contains only the headline identifying Acumen Pharmaceuticals’ Q3 2026 earnings call transcript; it gives no details about the call.

Why it matters — ABOS watchers would need the transcript’s substantive remarks to assess what the company reported or discussed.

Acumen Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 26 Oct 2026neutral

Acumen Pharmaceuticals said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody targeting soluble amyloid-beta oligomers in patients with Alzheimer’s disease.

Why it matters — The anticipated trial update is a key development for ABOS watchers tracking sabirnetug’s clinical progress.

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 26 Oct 2026neutral

Acumen Pharmaceuticals reported third-quarter 2026 financial results and business highlights. The company expects topline results from its Phase 2 ALTITUDE-AD study in November 2026, targets a mid-2027 IND filing for its EBD program lead candidate, and reported $78.6 million in cash, equivalents and marketable securities as of September 30, 2026.

Why it matters — ABOS watchers may track the timing of the ALTITUDE-AD results and EBD program filing, as well as the company’s stated cash position and expected runway into early 2027.

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewsWire · 22 Oct 2026neutral

Acumen Pharmaceuticals said it will present three posters at the 19th Annual CTAD conference, covering preliminary baseline characteristics and participant and care-partner experiences in its Phase 2 ALTITUDE-AD trial of sabirnetug. The conference is scheduled for November 16–19, 2026, in person and online.

Why it matters — The presentations will provide updates on participant characteristics and experiences in ABOS’s Phase 2 trial of sabirnetug for early Alzheimer’s disease.

FAQ

Frequently asked questions about ABOS stock

What is the ABOS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABOS stock a buy right now?

Of the 6 analysts covering Acumen Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acumen Pharmaceuticals, Inc. 62 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABOS?

As at 29 Oct 2026, Acumen Pharmaceuticals, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will ABOS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +249.3% from the last close, and Ticker Nerd's factor model ranks Acumen Pharmaceuticals, Inc. 62 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABOS stock forecast for 2030?

No analyst covering Acumen Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.

How has ABOS stock performed over the past year?

Acumen Pharmaceuticals, Inc. returned +1.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acumen Pharmaceuticals, Inc. do?

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease.

What is the latest news on ABOS?

The most recent item we track (Seeking Alpha, 28 Oct 2026): "Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout". Seeking Alpha rates Acumen Pharmaceuticals a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. The article estimates fair value at $2.57 per share and says the thesis depends on efficacy and manageable ARIA risk.

Company

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.

CEO Mr. Daniel J. O'Connell M.B.A. · 60 employees · United States · https://acumenpharm.com